奥赛康(002755) - 2024 Q2 - 季度业绩预告

Financial Performance - The company expects a net profit attributable to shareholders of between 66 million and 85 million yuan for the first half of 2024, compared to a loss of 158.45 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 45 million and 58 million yuan, compared to a loss of 183.54 million yuan in the previous year[3]. - Basic earnings per share are expected to be between 0.07 yuan and 0.09 yuan, recovering from a loss of 0.17 yuan per share in the same period last year[3]. Revenue Growth - The increase in revenue is attributed to rapid sales growth in anti-infection and chronic disease products, leading to improved profitability[5]. Cost Management - The company has achieved significant cost control by optimizing various expenses, resulting in reduced production, sales, and management costs[6]. - Research and development expenses have decreased due to the completion of significant clinical research phases for some new drugs, allowing the company to focus on key advantageous products[5]. Caution for Investors - The performance forecast is based on preliminary estimates by the finance department and has not been audited by the accounting firm[4]. - Investors are advised to make cautious decisions and be aware of investment risks as the final financial data will be disclosed in the 2024 semi-annual report[7].